WDR6 and breast cancer: The results showed that in Kaplan−Meier plotter and PrognoScan databases, Relapse‐free survival (RFS), postprogression survival (PPS), and distant metastases‐free survival (DMFS) of breast cancer patients in the WDR6 high‐expression group were all significantly longer than the WDR6 low‐expression group (Figure 2A−C).